MX2020006451A - Tratamiento de la fibrosis con inositol. - Google Patents
Tratamiento de la fibrosis con inositol.Info
- Publication number
- MX2020006451A MX2020006451A MX2020006451A MX2020006451A MX2020006451A MX 2020006451 A MX2020006451 A MX 2020006451A MX 2020006451 A MX2020006451 A MX 2020006451A MX 2020006451 A MX2020006451 A MX 2020006451A MX 2020006451 A MX2020006451 A MX 2020006451A
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- inositol
- treatment
- reactive
- subject
- Prior art date
Links
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 title abstract 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 title abstract 3
- 229960000367 inositol Drugs 0.000 title abstract 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 title abstract 3
- 206010016654 Fibrosis Diseases 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 206010048654 Muscle fibrosis Diseases 0.000 abstract 2
- 230000009787 cardiac fibrosis Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere al uso médico de inositol para el tratamiento de la fibrosis muscular reactiva, por ejemplo, fibrosis cardiaca reactiva, en un sujeto. La presente invención se refiere además a métodos para el tratamiento de la fibrosis muscular reactiva, por ejemplo, fibrosis cardiaca reactiva mediante la administración de inositol a un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT201700148902 | 2017-12-22 | ||
| PCT/EP2018/086182 WO2019122119A1 (en) | 2017-12-22 | 2018-12-20 | Treatment of fibrosis with inositol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006451A true MX2020006451A (es) | 2020-11-06 |
Family
ID=61731767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006451A MX2020006451A (es) | 2017-12-22 | 2018-12-20 | Tratamiento de la fibrosis con inositol. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200390723A1 (es) |
| EP (1) | EP3727359B1 (es) |
| BR (1) | BR112020012687A2 (es) |
| CA (1) | CA3085612A1 (es) |
| ES (1) | ES2981316T3 (es) |
| MA (1) | MA51276A (es) |
| MX (1) | MX2020006451A (es) |
| WO (1) | WO2019122119A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245755B1 (en) * | 1992-04-21 | 2001-06-12 | Curators Of The Unversity Of Missouri | Use of aldosterone antagonists to inhibit myocardial fibrosis |
| US6039967A (en) | 1997-04-03 | 2000-03-21 | Point Biomedical Corporation | Intravesical drug delivery system |
| JP2012532879A (ja) * | 2009-07-07 | 2012-12-20 | ノームオキシーズ，インコーポレイテッド | イノシトールトリピロリン酸を使用して多剤耐性を低減する方法 |
| ITUA20163025A1 (it) * | 2016-04-29 | 2017-10-29 | Sochim Int S P A | Composizione per il trattamento della sindrome dell’ovaio policistico |
-
2018
- 2018-12-20 ES ES18822360T patent/ES2981316T3/es active Active
- 2018-12-20 BR BR112020012687-0A patent/BR112020012687A2/pt not_active Application Discontinuation
- 2018-12-20 MX MX2020006451A patent/MX2020006451A/es unknown
- 2018-12-20 MA MA051276A patent/MA51276A/fr unknown
- 2018-12-20 CA CA3085612A patent/CA3085612A1/en active Pending
- 2018-12-20 US US16/955,220 patent/US20200390723A1/en not_active Abandoned
- 2018-12-20 WO PCT/EP2018/086182 patent/WO2019122119A1/en not_active Ceased
- 2018-12-20 EP EP18822360.6A patent/EP3727359B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3085612A1 (en) | 2019-06-27 |
| EP3727359B1 (en) | 2024-04-17 |
| ES2981316T3 (es) | 2024-10-08 |
| WO2019122119A1 (en) | 2019-06-27 |
| EP3727359A1 (en) | 2020-10-28 |
| US20200390723A1 (en) | 2020-12-17 |
| MA51276A (fr) | 2021-04-21 |
| EP3727359C0 (en) | 2024-04-17 |
| BR112020012687A2 (pt) | 2020-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502793A1 (en) | Aadc polynucleotides for the treatment of parkinson`s disease | |
| MX2017005834A (es) | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. | |
| PH12017500746B1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
| MY186977A (en) | Tetrasubstituted alkene compounds and their use | |
| EP4570314A3 (en) | Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure | |
| PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
| ZA202503350B (en) | Semaglutide in medical therapy | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2019000677A (es) | Células miméticas de células b. | |
| SG10201804034QA (en) | Methods for treating hypotension | |
| ZA201704327B (en) | Methods and compositions for treating brain diseases | |
| TW201613544A (en) | Treatment device and chair | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| EP4249056A3 (en) | Method for treating heart failure | |
| TW201613639A (en) | Methods for treating cardiovascular diseases | |
| MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
| MX382608B (es) | Tratamiento del prurito urémico. | |
| MX2017004842A (es) | Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica). | |
| TW201613569A (en) | Composition consisting of kukoamine A and/or kukoamine B and method of using thereof | |
| WO2015142865A3 (en) | Metakaryocidal treatments | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| MX2020006451A (es) | Tratamiento de la fibrosis con inositol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: LO.LI. PHARMA S.R.L. |